BofA raised the firm’s price target on Pharvaris (PHVS) to $30 from $27 and keeps a Neutral rating on the shares. The company reported positive topline results for the Phase 3 RAPIDe-3 study, with the study meeting its primary endpoint, the analyst tells investors in a research note. The firm thinks additional upside will likely be contingent on positive phase 3 results for decuri’ XR in prophylactic HAE.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris price target raised to $41 from $37 at Morgan Stanley
- Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
- Pharvaris price target raised to $38 from $28 at Leerink
- Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
- Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating